Shenzhen Targetrx Inc. has patented proteolysis targeting chimeras (PROTACs) comprising cereblon ligands coupled to a hepatocyte growth factor receptor (HGFR, MET)-targeting moiety via linker acting as HGFR degradation inducers potentially useful for the treatment of cancer.